Top

Published in:

01-08-2005 | Original Article

β-Catenin and Met Deregulation in Childhood Hepatoblastomas

Authors: Sarangarajan Ranganathan, Xinping Tan, Satdarshan P. S. Monga

Published in: Pediatric and Developmental Pathology | Issue 4/2005

ABSTRACT

Activation of the Wnt/β-catenin and hepatocyte growth factor/Met signaling has been implicated in various tumors. Owing to the cross-talk between these pathways and aberrant redistribution of β-catenin in hepatoblastomas, we examined their status in this tumor. This study examined changes in β-catenin and Met in paired pretreatment and post-treatment hepatoblastoma tissues in relation to their effects on proliferation and target genes such as c-myc and cyclin-D1. In this study we compared proliferation indices, β-catenin staining and its known molecular targets, c-myc and cyclin-D1, and Met, a tyrosine kinase receptor for hepatocyte growth factor in pretreatment and post-treatment specimens. Pretreatment and post-treatment sections from 13 children, ages 11 weeks to 9 years, were analyzed for these markers by immunohistochemistry. All tumors (13 of 13) displayed increased proliferation and β-catenin (cytoplasmic and nuclear) staining in pretreatment biopsies that remained relatively unaffected after treatment. Aberrant Met staining (cytoplasmic) was observed in all pretreatment samples that decreased considerably after treatment in 11 of 13 patients. A significant subset of these tumors showed increased c-myc and cyclin-D1 staining in pretreatment biopsies that decreased after chemotherapy in most cases. β-Catenin redistribution in tumor cells corresponds to proliferation in hepatoblastomas. However, β-catenin nuclear localization remains unaffected in viable hepatoblastoma tissue after chemotherapy. In contrast, Met undergoes a prominent decrease after treatment and thus might be important in pathogenesis of hepatoblastoma.

Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003;38:560–566CrossRef

Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983;14:512–537PubMed

Ross JA, Gurney JG. Hepatoblastoma incidence in the United States from 1973 to 1992. Med Pediatr Oncol 1998;30:141–142CrossRefPubMed

von Schweinitz D, Wischmeyer P, Leuschner I, et al. Clinico-pathological criteria with prognostic relevance in hepatoblastoma. Eur J Cancer 1994;30A:1052–1058CrossRefPubMed

Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol 1997;15:1190–1197PubMed

Ohama K, Nagase H, Ogino K, et al. Alpha-fetoprotein (AFP) levels in normal children. Eur J Pediatr Surg 1997;7:267–269PubMed

Udatsu Y, Kusafuka T, Kuroda S, Miao J, Okada A. High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int 2001;17:508–512CrossRefPubMed

Miao J, Kusafuka T, Udatsu Y, Okada A. Sequence variants of the Axin gene in hepatoblastoma. Hepatol Res 2003;25:174–179CrossRefPubMed

Blaker H, Hofmann WJ, Rieker RJ, Penzel R, Graf M, Otto HF. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999;25:399–402CrossRefPubMed

10.

Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000;152:45–51CrossRefPubMed

11.

Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269–273PubMed

12.

Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000;19:498–504CrossRefPubMed

13.

Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, Michalopoulos GK. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003;124:202–216CrossRefPubMed

14.

Monga SP, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001;33:1098–1109CrossRefPubMed

15.

de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847–8851CrossRefPubMed

16.

Hussain SZ, Sneddon T, Tan X, Micsenyi A, Michalopoulos GK, Monga SP. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004;292:157–169CrossRefPubMed

17.

Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286–3305PubMed

18.

Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002;296:1644–1646CrossRefPubMed

19.

Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis–a look outside the nucleus. Science 2000;287:1606–1609CrossRefPubMed

20.

Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837–1851PubMed

21.

Jou TS, Stewart DB, Stappert J, Nelson WJ, Marrs JA. Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex. Proc Natl Acad Sci USA 1995;92:5067–5071PubMed

22.

Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064–2071PubMed

23.

Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307–310PubMed

24.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915–925CrossRefPubMed

25.

Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin’s adhesive and transcriptional functions. Genes Dev 2004;18:2225–2230CrossRefPubMed

26.

Duchesne C, Charland S, Asselin C, Nahmias C, Rivard N. Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells. J Biol Chem 2003;278:14274–14283CrossRefPubMed

27.

Park WS, Oh RR, Park JY, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 2001;193:483–490CrossRefPubMed

28.

Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 2001;7:901–908PubMed

29.

Kuniyasu H, Yasui W, Shimamoto F, et al. Hepatoblastoma in an adult associated with c-met proto-oncogene imbalance. Pathol Int 1996;46:1005–1010PubMed

30.

Heifetz SA, French M, Correa M, Grosfeld JL. Hepatoblastoma: the Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations. Pediatr Pathol Lab Med 1997;17:857–874CrossRefPubMed

31.

Finegold MJ. Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice. Med Pediatr Oncol 2002;39:484–46CrossRefPubMed

32.

Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18:2665–2675PubMed

33.

Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 2002;39:530–535CrossRefPubMed

34.

Rugge M, Sonego F, Pollice L, et al. Hepatoblastoma: DNA nuclear content, proliferative indices, and pathology. Liver 1998;18:128–133PubMed

35.

Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41–59CrossRefPubMed

36.

Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60:6737–6743PubMed

37.

Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309–325CrossRefPubMed

38.

Reyes JD, Carr B, Dvorchik I, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 2000;136:795–804CrossRefPubMed

39.

Brotto M, Finegold MJ. Distinct patterns of p27/KIP 1 gene expression in hepatoblastoma and prognostic implications with correlation before and after chemotherapy. Hum Pathol 2002;33:198–205CrossRefPubMed

40.

Ljubimova JY, Petrovic LM, Wilson SE, Geller SA, Demetriou AA. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 1997;45:79–87PubMed

41.

Skouteris GG, Schroder CH. C-myc is required for the G0/G1-S transition of primary hepatocytes stimulated with a deleted form of hepatocyte growth factor. Biochem J 1996;316(pt 3):879–886PubMed

42.

Clifford SC, Czapla K, Richards FM, O’Donoghue DJ, Maher ER. Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Br J Cancer 1998;77:1420–1428PubMed

43.

Albrecht JH, Rieland BM, Nelsen CJ, Ahonen CL. Regulation of G(1) cyclin-dependent kinases in the liver: role of nuclear localization and p27 sequestration. Am J Physiol 1999;277:G1207–G1216PubMed

44.

Allen RE, Sheehan SM, Taylor RG, Kendall TL, Rice GM. Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. J Cell Physiol 1995;165:307–312CrossRefPubMed

45.

Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002;21:1000–1008CrossRefPubMed

Title: β-Catenin and Met Deregulation in Childhood Hepatoblastomas
Authors: Sarangarajan Ranganathan
Xinping Tan
Satdarshan P. S. Monga
Publication date: 01-08-2005
Publisher: Springer-Verlag
Published in: Pediatric and Developmental Pathology / Issue 4/2005
Print ISSN: 1093-5266
Electronic ISSN: 1615-5742
DOI: https://doi.org/10.1007/s10024-005-0028-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

β-Catenin and Met Deregulation in Childhood Hepatoblastomas

ABSTRACT

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ABSTRACT

Please log in to get access to this content

Other articles of this Issue 4/2005

Early Onset of Lysosomal Storage Disease in a Murine Model of Mucopolysaccharidosis Type VII: Undegraded Substrate Accumulates in Many Tissues in the Fetus and Very Young MPS VII Mouse

Pulmonary Interstitial Hemosiderin in Infancy: A Common Consequence of Normal Labor

Tuboovarian Abscess in a 7-Year-Old Girl With Markedly Increased Tumor Markers in the Absence of Malignancy

Unusual Adrenal Cortical Tumor of Unknown Biologic Potential: A Nodule in a Nodule in a Nodule

Cutaneovisceral Angiomatosis With Thrombocytopenia

Multinucleated Foreign Body Giant Cells in Placental Membrane